SOUTH SAN FRANCISCO, Calif., April 9, 2015 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials to treat multi-drug resistant (MDR) gram-negative infections, announced today that it will present at the 14th Annual Needham Healthcare Conference in New York, New York. Dr. Kenneth Hillan, Chief Executive Officer, will provide an update on the development plan for their lead program, plazomicin, which in addition to its ongoing Phase 3 trial in carbapenem-resistant Enterobacteriaceae (CRE), now includes a Phase 3 study in complicated urinary tract infections (cUTI) that Achaogen expects to serve as a pivotal study to support the filing of a New Drug Application with the US Food and Drug Administration. The presentation will take place on Wednesday, April 15th at 10:40 a.m. Eastern Time, at the Westin NY Grand Central Hotel.
A live webcast of the presentation can be accessed by visiting the investor relations section of the Achaogen website at http://investors.achaogen.com/. A replay of the webcast will be archived for at least 30 days following the presentation.
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterials to treat MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen's lead product candidate, for the treatment of serious lung, bloodstream, and urinary tract infections due to Enterobacteriaceae, including CRE. Achaogen's plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen's gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections.
All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including Achaogen's expectations regarding the success of its proposed Phase 3 cUTI trial for plazomicin. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause Achaogen's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical development process; specific risks related to the proposed Phase 3 cUTI trial of plazomicin, including the risks and uncertainties of the regulatory approval process. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Achaogen's business in general, see Achaogen's reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2014.
CONTACT: Candice Knoll Blueprint Life Science Group 415.375.3340 Ext. 105 email@example.com